ALTICE MAY LOOK TO BUY VERIZON’S WIRELINE OPERATIONS, CITI SAYS
*DIJSSELBLOEM SAYS CREDITORS STILL FAR FROM A DEAL WITH GREECE
Gapping down In reaction to disappointing earnings/guidance: SOL -6.3%, DAKT -5.4%, QUNR -2.4%, ODFL -2.1%, (announces May 2015, LTL tons per day have increased 9.6% Y/Y; co revises expectations for Q2 LTL to +9.5-10% Y/Y)
Select Airline related names showing weakness: DAL -1.9%, UAL -1.7%, LUV -1.1%
Other news: HERO -8.1% (announced rate reductions for Hercules 261, Hercules 262 and Hercules 266 contracts), RGLS -6.6% (Kleanthis G. Xanthopoulos to step down as President and CEO; Paul Grint appointed President and CEO), TUBE -5.5% (filed for $75 mln offering of common stock), CG -3.8% (files for offering of common units representing limited partner interests; announces an offering of 7 mln common units), IBN -3% (Sensex down 2.5% overnight), AER -2.7% (announced launch of an underwritten secondary offering by AIG of 50 mln ordinary shares; co to repurchase $750 mln of the shares being sold by AIG), CERU -2.6% ( announces that full data from a Phase 1b/2 investigator-sponsored trial of CRLX101 in combination with Avastin® (bevacizumab) in metastatic renal cell carcinoma, or RCC, was presented), BXMT -2.6% (announces pricing of its 10 mln offering of common stock), QTS -2.1% ( announces public offering of 5.5 mln shares of common stock), FGP -1.7% (co has commenced an underwritten public offering of 6.325 mln common units; also announced its operating subsidiary will offer $400 mln in aggregate principal amount of senior unsecured notes due 2023), IFN -1.5% (Sensex down 2.5% overnight), CEL -1% (announces controlling sharehoder announcement regarding co's possible rights offering)
Analyst comments: CTRP -4.1% (downgraded to Hold at Stifel), IRM -1.4% (downgraded to Underperform from Hold at Jefferies), INTC -0.9% (downgraded to Market Perform from Outperform at BMO Capital)
Gapping up In reaction to strong earnings/guidance: CBRL +4.5%, HTGM +4.2%, (also HTG Molecular Diagnostics and MD Anderson Cancer Center enter into a sponsored research agreement to investigate new molecular diagnostics for lung cancer ), CONN +4.1%, PVH +3.5%, DG +3%, MDT +0.6%, AMWD +0.4%
M&A news: TA +10.8% (enters sale leaseback transactions wtih Hospitality Properties Trust (HPT); expects net proceeds of $352 million), JUNO +1.7% (acquisition of X-BODY, Inc for initial consideration of approx $21 mln in cash and 439,265 shares ofJuno stock)
Select EU financial related names showing strength: SAN +2.3%, CS +2.3%, ING +1.9%, DB +1.7%, NBG +1.5%
Select oil/gas related names showing strength: MPET +6.8%, STO +2.3%, TOT +1.9%, SDRL +1.7%, RIG +1.6%, WLL +0.8%
Other news: AVEO +10.5% (Cigna (CI) announces will now cover Biodesix' Veristat), DRNA +8.2% (presented preliminary safety and efficacy data from DCR-MYC Phase 1 study in patients with advanced solid tumors at ASCO: Evidence of clinical anti-tumor activity seen in two patients with advanced pancreatic neuroendocrine tumors), HTGC +7.2% (announced that Robert Lake has joined the Co as chief credit officer), YGE +5.8% (announces it has been chosen as a preferred supplier to Vivint Solar (VSLR)), PLUG +5.6% (announces an expansion contract with Walmart (WMT) Canada), YOKU +4.9% (partners with Disney (DIS) for its Marvel marketing platform in China), NQ +2.6% (still checking), TS +2.5% (issues restatement for 2014), CS +2.4% (still checking), PBR +1.6% (announced the pricing of its 100-year Global Notes denominated in USD), BBRY +1.3% (slightly rebounding following yday's decline)
Analyst comments: VICL +11.9% (initiated with a Buy at ROTH Capital; tgt $4.65), ZION +5.6% (upgraded to Buy from Neutral at Guggenheim; upgraded to Buy from Underperform at Credit Agricole), SN +2.3% (upgraded to Buy from Accumulate at KLR Group ), BIG +1.8% (upgraded to Overweight from Equal Weight at Barclays), ONTY +1.3% (postive comments at Mizuho), TTMI +1% (resumed with a Overweight at JP Morgan), WLL +0.7% (initiated with a Buy at Evercore ISI), BUD +0.5% (upgraded to Positive from Neutral at Susquehanna)
2015-06-02 12:21:49.154 GMT
By Gaurav Panchal
(Bloomberg) -- Aveva, Hunting had the highest short
interest among potential European takeover targets mentioned in
broker notes, media reports in May.
* Hikma, GlaxoSmithKline saw the biggest rise in short
interest as a % of shares outstanding
HIGHEST SHORT INTEREST:
* Aveva short interest as % of shrs outstanding fell to 2.28%
as of May 29 from 3.1% on May 1
*
* Co.’s largest short positions is held by Bluecrest
Capital (-0.47%) according to filing dated May 26
* May 17: Sunday Times reported Schneider Electric in
talks about possible Aveva bid
*
* May 19: Aveva CEO said not in takeover talks with
speculated suitors
* Hunting short interest as % of shrs outstanding rose to 1.3%
as of May 29 from ~1% on May 1
*
* Co.’s largest short positions is held by Ardevora Asset
Management (-0.6%) according to filing dated March 9
* May 14: Hunting mentioned in merger talk in U.K.
newspapers
BIGGEST 1-Month SI Increase:
* Hikma short interest increased by 256,000 last month, was
0.13% of shrs outstanding on May 1
*
* May 20: Hikma mentioned in merger talk in U.K.
Newspapers
* GlaxoSmithKline short interest increased by 4.3m last month,
was 0.23% of shrs outstanding on May 1
*
* GlaxoSmithKline mentioned in merger talk in U.K.
newspapers
NOTES:
* Cos. mentioned as takeover/merger candidates exclude already
announced approaches/deals, but not rejected/failed deals,
excludes cos mentioned in M&A survey, unless mentioned
elsewhere
* Individual institutional short selling data is sourced from
regulatory fillings, aggregate short interest data sourced
from Markit
* For regulatory filings on short selling, run SPOS<GO>
* Imagination, Lancashire Most-Shorted Among April EU M&A
Targets
For Related News and Information:
First Word scrolling panel: FIRST<GO>
First Word newswire: NH BFW<GO>
To contact the reporter on this story:
Gaurav Panchal in London at +44-20-3525-0511 or
gpanchal2@bloomberg.net
- Reports Q3 (Apr) earnings of $1.49 per share, $0.12 better than the Capital IQ Consensus of $1.37; revenues rose 6.3% year/year to $683.7 mln vs the $680.04 mln consensus.
- Comparable store restaurant sales increased 5.2%, including a 3.4% increase in average check. Average menu prices for the quarter were approximately 2.5% higher than in the prior year quarter. Comparable store retail sales increased 4.5% for the quarter.
- Co issues in-line guidance for Q4, sees EPS of $1.75-1.85 vs. $1.78 Capital IQ Consensus.
- Co issues guidance for FY15, raises EPS to $6.60-6.70 from $6.40-6.50 vs. $6.55 Capital IQ Consensus; reaffirms FY15 revs of $2.80-2.85 bln vs. $2.84 bln Capital IQ Consensus; projected increases in comparable store restaurant sales of between 4.5% and 5.0%, and comparable store retail sales of between 3.5% and 4.0%.
- Board of Directors increased the quarterly dividend to $1.10 per share on the Company's common stock, which represents a 10% increase over the Company's previous quarterly dividend of $1.00. The Board of Directors also declared a special dividend of $3.00 per share on the Company's common stock. Both the quarterly dividend and the special dividend are payable on August 5, 2015, to shareholders of record on July 17, 2015.
Gapping down: RGLS -9.3%, HERO -8.1%, TUBE -7.8%, PPL -6.5%, SOL -5.6%, CG -4.3%, CEL -3.6%, CTRP -3.2%, IBN -2.9%, QTS -2.7%, CERU -2.6%, BXMT -2.5%, QUNR -2.2%, ODFL -2.1%, FGP -1.3%, DEO -1.3%, TSEM -1.3%, AA -1.1%, AER -1%, GOLD -1%, BHP -1%